Last update March 29, 2016
Selective estrogen receptor modulator. Estrogen agonist in bone and estrogen receptor antagonist in breast and uterine tissue.
Indicated in treating osteoporosis and preventing breast cancer.
Raloxifene does not alter prolactin secretion in premenopausal women but increases levels of estradiol and sex-hormone binding globulin (BGSH).
At last update no published data on excretion in breast milk were found.
Pharmacokinetic data (large volume of distribution, moderately high molecular weight and high percentage of protein binding) make it unlikely milk passage of significant amounts.
Low oral bioavailability hinders the passage into infant plasma from ingested milk except in preterm neonates and immediate neonatal period, because an increased intestinal permeability can appear.
Although short-term treatments may be of low risk during breastfeeding, the anti-estrogenic effect on breast tissue, a prolonged use is not recommended.
We do not have alternatives for Raloxifene Hydrochloride.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2006 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM